SynAm Vaccine, located in Rockville, Maryland, is a pioneering biotech company dedicated to eradicating pneumococcal diseases such as pneumonia, middle ear infections, and meningitis through the development of the world's first universal vaccine. Their lead vaccine candidate provides universal coverage against all 91 bacteria serotypes, addressing a critical unmet medical need in the market.
With a mission to combat serious illnesses in children and adults worldwide, SynAm Vaccine's innovative approach surpasses current vaccines that only cover a fraction of the serotypes. Their team of experienced scientists and medical advisors, including Nobel laureates, ensures the highest level of expertise in their research and development efforts.
Generated from the website